Clinical Trial: Study of Afimoxifene Gel to Treat Cyclic Mastalgia in Premenopausal Women

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase II, Randomized, Double-Blind, Two-Dose, Placebo-Controlled Multicentre Study of 4-Hydroxy Tamoxifen Gel for Cyclical Mastalgia in Otherwise Healthy Pre-Menopausal

Brief Summary: The purpose of this study is to evaluate the efficacy of two doses of 4-hydroxy tamoxifen (4-OHT) compared with placebo on the intensity of cyclic mastalgia in pre-menopausal women with regular menstrual cycles who are not taking oral contraceptives.

Detailed Summary:

This study is a Phase II, randomised, double-blind, placebo-controlled, two-dose, multicentre trial of 4-OHT gel in approximately 130 otherwise healthy pre-menopausal women with a history of cyclical mastalgia, peaking during the second half of the menstrual cycle and decreasing significantly with the onset of menstruation, during the four months prior to study entry.

The primary efficacy endpoint in this study is change in change in average pain Visual Analog Scale (VAS) scores for the seven worst pain scores within a cycle, from baseline to the fourth cycle after start of treatment.


Sponsor: ASCEND Therapeutics

Current Primary Outcome: Change in Visual Analog Scale (VAS) scores for the seven worst scores within a cycle, from baseline to the forth cycle after treatment

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Change from baseline in average VAS pain scores for the seven worst pain scores within a cycle over all cycles
  • Change from baseline in average VAS pain scores over all scores over all cycles
  • Change from baseline in the number of nominal days of breast pain (NDBP) over all cycles using the Cardiff Breast Pain Chart.
  • Physician's global assessment of pain.
  • Physician's clinical evaluation of mastalgia (tenderness determined by palpation).
  • Physician's clinical evaluation of mastalgia (nodularity).
  • Patient's global assessment of pain.


Original Secondary Outcome: Same as current

Information By: ASCEND Therapeutics

Dates:
Date Received: January 5, 2006
Date Started: March 2003
Date Completion:
Last Updated: July 11, 2013
Last Verified: July 2013